Literature DB >> 26603210

Pulmonary embolism, acute coronary syndrome and ischemic stroke in the Spanish National Discharge Database.

Ricardo Guijarro1, Javier de Miguel-Diez2, David Jimenez3, Javier Trujillo-Santos4, Remedios Otero5, Raquel Barba6, Manuel Monreal7.   

Abstract

BACKGROUND: Venous and arterial thrombosis share a number of pathogenic mechanisms, but the burden of pulmonary embolism (PE) has not been consistently compared with that in other arterial diseases.
METHODS: We used the Spanish National Discharge Database to compare the frequency, clinical characteristics and mortality rate of all patients with PE, acute coronary syndrome (ACS) or ischemic stroke admitted from 2001 to 2010. Patients were classified as having primary diagnosis (the process leading to hospital admission) or secondary diagnosis (it appeared during hospital stay for other reasons)
RESULTS: During the study period, 31,949,739 patients were discharged. Of these, 165,229 (0.52%) were diagnosed with PE, 562,837 (1.76%) with ACS and 495,427 (1.55%) with ischemic stroke. Overall, 31% of patients with PE, 8.4% with ACS and 13% with ischemic stroke had secondary diagnoses. The most common reasons for admission in patients with secondary PE were: cancer (21%), acute respiratory failure (11%), acute heart failure (6.4%) and stroke (5.5%). Mean hospital stay was: 14 ± 13 days in PE patients, 9.7 ± 9.7 in those with ACS and 13 ± 14 days in those with stroke. In-hospital mortality rate was: 10.5%, 10.1% and 12.3% respectively in patients with primary diagnosis, and 36%, 34% and 29% in those with secondary diagnosis.
CONCLUSIONS: Patients hospitalized with PE were 3-4 times less frequent than those with ACS or stroke, but had a higher mortality. One in every 3 patients with PE (but only one in every 10 with ACS or stroke) had secondary diagnosis, and these patients had the highest mortality.
Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Ischemic stroke; Mortality; Prevention; Pulmonary embolism

Mesh:

Year:  2015        PMID: 26603210     DOI: 10.1016/j.ejim.2015.10.006

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  3 in total

1.  Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.

Authors:  Javier Trujillo-Santos; Francisco Martín Martos; Carme Font; Dominique Farge-Bancel; Vladimir Rosa; Alicia Lorenzo; Manuel Barrón; Manuel Alejandro Lorente; José María Pedrajas; Manuel Monreal
Journal:  Heliyon       Date:  2017-01-16

Review 2.  Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.

Authors:  Benjamin Brenner; Russell Hull; Roopen Arya; Jan Beyer-Westendorf; James Douketis; Ismail Elalamy; Davide Imberti; Zhenguo Zhai
Journal:  Thromb J       Date:  2019-04-15

3.  Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa.

Authors:  Fakiha Siddiqui; Darko Antic; Alfonso Tafur; Emily Bontekoe; Debra Hoppensteadt; Grigoris Gerotziafas; Ismail Elalamy; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.